ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina)

Journal of the American College of Cardiology

Volumn 36, Issue 3, 2000, Pages 970-1062

  Braunwald, Eugene ^a   Antman, Elliott M ^a   Beasley, John W ^a   Califf, Robert M ^a   Cheitlin, Melvin D ^a   Hochman, Judith S ^a   Jones, Robert H ^a   Kereiakes, Dean ^a   Kupersmith, Joel ^a   Levin, Thomas N ^a   Pepine, Carl J ^a   Schaeffer, John W ^a   Smith III, Earl E ^a   Steward, David E ^a   Theroux, Pierre ^a   Gibbons, Raymond J ^a   Alpert, Joseph S ^a   Eagle, Kim A ^a   Faxon, David P ^a   Fuster, Valentin ^a   Gardner, Timothy J ^a   Gregoratos, Gabriel ^a   Russell, Richard O ^a   Smith Jr , Sidney C ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; CLOPIDOGREL; COCAINE; CREATINE KINASE; FIBRINOGEN RECEPTOR ANTAGONIST; MORPHINE SULFATE; MYOGLOBIN; NITRATE; TICLOPIDINE; TROPONIN;

ANAMNESIS; ANGIOCARDIOGRAPHY; CLINICAL FEATURE; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DISEASE CLASSIFICATION; ELECTROCARDIOGRAM; EXERCISE TEST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL CARE; HOSPITAL DISCHARGE; HUMAN; MEDICAL ASSESSMENT; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYNDROME X; UNSTABLE ANGINA PECTORIS;

EID: 0033851626     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00889-5     Document Type: Review

References (525)

1. One-year results of the Thrombolysis In Myocardial Infarction (TIMI) IIIB clinical trial: A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction
2. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). 1999 update
3. National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the use of cardiac markers in coronary artery diseases
4. Unstable angina: An etiologic approach to management
5. Unstable angina: A classification
6. Grading of angina pectoris
7. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators: Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
8. Use of the acute cardiac ischemia time-insensitive predictive instrument (ACI-TIPI) to assist with triage of patients with chest pain or other symptoms suggestive of acute cardiac ischemia: A multicenter, controlled clinical trial
9. Delay between onset of chest pain and arrival to the coronary care unit among minority and disadvantaged patients
10. Prehospital prophylactic lidocaine does not favorably affect outcome in patients with chest pain
11. Early discharge in the thrombolytic era: An analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial
12. Factors influencing the time to administration of thrombolytic therapy with recombinant tissue plasminogen activator (data from the National Registry of Myocardial Infarction). Participants in the National Registry of Myocardial Infarction
13. Prehospital-initiated vs hospital-initiated thrombolytic therapy: The Myocardial Infarction Triage and Intervention Trial
14. Clinical features of emergency department patients presenting with symptoms suggestive of acute cardiac ischemia: A multicenter study
15. Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction
16. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Result of the TIMI IIIB trial. Thrombolysis In Myocardial Ischemia
17. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP)
18. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
19. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy
20. Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS)
21. Estimating the likelihood of significant coronary artery disease
22. Value of the history and physical in identifying patients at increased risk for coronary artery disease
23. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina
24. Acute chest pain in the emergency room: Identification and examination of low-risk patients
25. A predictive instrument to improve coronary-care-unit admission practices in acute ischemic heart disease: A prospective multicenter clinical trial
26. A tool for judging coronary care unit admission appropriateness, valid for both real-time and retrospective use. A time-insensitive predictive instrument (TIPI) for acute cardiac ischemia: A multicenter study
27. Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial): Global Utilization of Streptokinase and TPA for Occluded Arteries
28. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators
29. Outcome and profile of women and men presenting with acute coronary syndromes a report from TIMI IIIB. TIMI Investigators. Thrombolysis In Myocardial Infarction
30. Differences between men and women in the management of unstable angina pectoris (the GUARANTEE Registry). The GUARANTEE Investigators
31. Effect of age on outcome with primary angioplasty versus thrombolysis
32. Age and outcome with contemporary thrombolytic therapy: Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial
33. Do patients' coronary risk factor reports predict acute cardiac ischemia in the emergency department?. A multicenter study
34. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
35. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction Analyses of patient subgroups in the Thrombolysis In Myocardial Infarction (TIMI) trial, phase II
36. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial
37. Acute myocardial infarction in the young - The role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial
38. The use of empiric clinical data in the evaluation of practice guidelines for unstable angina
39. Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease
40. Prognostic value of a coronary artery jeopardy score
41. Comparison of the natural history of new onset and exacerbated chronic ischemic heart disease. The Chest Pain Study Group
42. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK: An international randomized trial of emergency PTCA/CABG-trial design. The SHOCK Trial Study Group
43. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation
44. An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: A report from a National Heart Attack Alert Program Working Group
45. Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspecific electrocardiograms (a report from the Multicenter Chest Pain Study)
46. Unstable angina and non-Q wave myocardial infarction: Does the clinical diagnosis have therapeutic implications?
47. Prognostic value of the admission electrocardiogram in acute coronary syndromes
48. Impact of the availability of a prior electrocardiogram on the triage of the patient with acute chest pain
49. Diagnostic and prognostic importance of comparing the initial to the previous electrocardiogram in patients admitted for suspected acute myocardial infarction
50. Biochemical markers of myocardial injury: Is MB creatine kinase the choice for the 1990s?
51. Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina
52. Acute myocardial infarction with isolated ST-segment elevation in posterior chest leads V7-9: 'hidden' ST-segment elevations revealing acute posterior infarction
53. Angiographic and clinical characteristics of patients with unstable angina showing an ECG pattern indicating critical narrowing of the proximal LAD coronary artery
54. Anatomic and prognostic significance of new T-wave inversion in unstable angina
55. Reversal of segmental hypokinesis by coronary angioplasty in patients with unstable angina, persistent T wave inversion, and left anterior descending coronary artery stenosis. Additional evidence for myocardial stunning in humans
56. Detecting acute cardiac ischemia in the emergency department: A review of the literature
57. Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings
58. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: Results of the TIMI III Registry ECG Ancillary Study. Thrombolysis In Myocardial Ischemia
59. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators
60. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes
61. Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression
62. Electrocardiographic and clinical predictors of acute myocardial infarction in patients with unstable angina pectoris
63. Utility of the prehospital electrocardiogram in diagnosing acute coronary syndromes: The Myocardial Infarction Triage and Intervention (MITI) Project
64. ST segment shift in unstable angina: Pathophysiology and association with coronary anatomy and hospital outcome
65. Relation of angiographic detected intracoronary thrombus and silent myocardial ischemia in unstable angina pectoris
66. Serial ECGs are less accurate than serial CK-MB results for emergency department diagnosis of myocardial infarction
67. Early continuous ST segment monitoring in unstable angina: Prognostic value additional to the clinical characteristics and the admission electrocardiogram
68. Long-term prognosis in unstable angina: The importance of early risk stratification using continuous ST segment monitoring
69. How did the acute ischemic heart disease predictive instrument reduce unnecessary coronary care unit admissions?
70. Clinical prediction rules: Applications and methodological standards
71. A computer-derived protocol to aid in the diagnosis of emergency room patients with acute chest pain
72. A computer protocol to predict myocardial infarction in emergency department patients with Chest pain
73. Ruling out acute myocardial infarction: A prospective multicenter validation of a 12-hour strategy for patients at low risk
74. Pre-hospital triage of patients with suspected myocardial infarction: Evaluation of previously developed algorithms and new proposals
75. Serum protein measurements and the diagnosis of acute myocardial infarction
76. Earlier diagnosis and treatment of acute myocardial infarction necessitates the need for a 'new diagnostic mind-set.'
77. Management of acute coronary syndromes based on risk stratification by biochemical markers: An idea whose time has come
78. Several conditions causing elevation of serum CK-MB and CK-BB
79. Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction
80. Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction
81. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I
82. Detection of unsuspected myocardial necrosis by rapid bedside assay for cardiac troponin T
83. Improved detection of minor ischemic myocardial injury with measurement of serum cardiac troponin I
84. Usefulness of positive troponin-T and negative creatine kinase levels in identifying high-risk patients with unstable angina pectoris
85. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina
86. Risk stratification in unstable coronary artery disease: Additive value of troponin T determinations and pre-discharge exercise tests. FRISK Study Group
87. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC Study Group
88. A comparison of cardiac troponin T and cardiac troponin I in patients with acute coronary syndromes
89. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: c7E3 Fab Antiplatelet-Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators
90. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management
91. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group
92. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: A Thrombolysis In Myocardial Infarction (TIMI) 11A substudy
93. The prognostic value of serum troponin T in unstable angina
94. Cardiac troponin T and cardiac troponin I: Relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators
95. The prognostic value of serum troponin T in unstable angina
96. Independent prognostic value of serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction: Analysis of 28 months of follow-up in 196 patients
97. Diagnostic performance and prognostic value of Serum troponin T in suspected acute myocardial-infarction
98. Prospective study of the role of cardiac troponin T in patients admitted with unstable angina
99. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease: TRIM Study Group. Thrombin Inhibition in Myocardial ischemia
100. Prognostic implications of detection of troponin I in patients with unstable angina pectoris
101. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies
102. Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris
103. Prognostic efficacy of troponin T measurement in angina pectoris
104. Early diagnosis of acute myocardial infarction in patients without ST-segment elevation
105. Strategies for the early diagnosis of acute myocardial infarction using biochemical markers
106. Diagnostic Marker Cooperative Study for the diagnosis of myocardial infarction
107. Clinical and analytical standardization issues confronting cardiac troponin I
108. Use of the combination of myoglobin and CK-MB mass for the rapid diagnosis of acute myocardial infarction
109. Early diagnosis and exclusion of acute myocardial infarction using biochemical monitoring. The BIOMACS Study Group. Biochemicals Markers of Acute Coronary Syndromes
110. A classification of unstable angina revisited
111. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction
112. Serial creatinine kinase (CK) MB testing during the emergency department evaluation of chest pain: Utility of a 2-hour deltaCK-MB of +1.6 ng/ml
113. Delta CK-MB outperforms delta troponin I at 2 hours during the initial EF evaluation of chest pain
114. Thrombin activity and early outcome in unstable angina pectoris
115. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarcytion (TIMI IIIB trial)
116. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy
117. C-reactive protein elevation and early outcome in patients with unstable angina pectoris
118. Elevated levels of interleukin-6 in unstable angina
119. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
120. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. Thrombolysis In Myocardial Infarction
121. Elevated levels of circulating soluble adhesion molecules in peripheral blood of patients with unstable angina
122. Critical pathways for acute coronary syndromes
123. American College of Emergency Physicians information paper: Chest pain units in emergency departments: A report from the Short-Term Observation Services Section
124. Management of observation units
125. Impact on the care of the emergency department chest pain patient from the Chest Pain Evaluation Registry (CHEPER) study
126. An emergency department-based protocol for rapidly ruling out myocardial ischemia reduces hospital time and expense: Results of a randomized study (ROMIO)
127. A clinical trial of a chest-pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators
128. The chest-pain unit - Ready for prime time
129. Cost-effectiveness of diagnostic strategies for patients with chest pain
130. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease
131. ACC/AHA guidelines for cardiac catheterization and cardiac catheterization laboratories. American College of Cardiology/American Heart Association Ad Hoc Task Force on Cardiac Catheterization
132. Stable Ischemic Syndromes
133. ACC/AHA expert consensus document: Use of sildenafil (Viagra) in patients with cardiovascular disease: American College of Cardiology/American Heart Association
134. Buccal versus intravenous nitroglycerin in unstable angina pectoris
135. Effect of intravenous nitrates on mortality in acute myocardial infarction: An overview of the randomised trials
136. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
137. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico
138. Rebound myocardial ischaemia following abrupt interruption of intravenous nitroglycerin infusion in patients with unstable angina at rest
139. Stable ischemic syndromes. Section 2: Clinical Cardiology (Section ed. Califf, RM)
140. Overview of results of randomized clinical trials in heart disease, II: Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification
141. Unstable angina: Ischemic Syndromes
142. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease
143. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: Results of a double-blind, randomized, multicenter trial
144. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: Findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT)
145. Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Danish Verapamil Infarction Trial (DAVIT) Study Group
146. Pharmacologic options for treatment of ischemic heart disease
147. Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: Is there a risk?
148. Verapamil use in patients with cardiovascular disease: An overview of randomized trials
149. Verapamil in acute myocardial infarction
150. Nifedipine and metoprolol in unstable angina: Findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT)
151. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview
152. Electrocardiographic subset analysis of diltiazem administration on long-term outcome after acute myocardial infarction. The Multicenter Diltiazem Post-Infarction Trial Research Group
153. Verapamil after myocardial infarction
154. Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction
155. Intravenous diltiazem in acute myocardial infarction: Diltiazem as Adjunctive Therapy to Activase (DATA) trial
156. Design of a placebo-controlled clinical trial of long-acting diltiazem and aspirin versus aspirin alone in patients receiving thrombolysis with a first acute myocardial infarction. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post-Thrombolysis (diltiazem) (INTERCEPT) Research Group
157. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
158. Effects of captopril on ischemic events after myocardial infarction: Results of the Survival and Ventricular Enlargement trial: SAVE Investigators
159. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials
160. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: A systematic overview of data from individual patients
161. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group
162. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
163. Clinical outcome of patients treated with spinal cord stimulation for therapeutically refractory angina pectoris. The Working Group on Neurocardiology
164. The multicenter study of enhanced external counterpulsation (MUST-EECP): Effect of EECP on exercise-induced myocardial ischemia and anginal episodes
165. EECP-enhanced external counterpulsation
166. Spinal Cord stimulation in chronic intractable angina pectoris: A randomized, controlled efficacy study
167. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a Clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization
168. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group
169. Enoxaparin prevents death and cardiac ischemic events in Unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial
170. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis
171. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes
172. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged anriplatelet therapy in various categories of patients
173. Inflammation; aspirin, and the risk of cardiovascular disease in apparently healthy men
174. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study
175. Aspirin, sulfinpyrazone, or both in unstable angina: Results of a Canadian multicenter trial
176. Aspirin, heparin, or both to treat acute unstable angina
177. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
178. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group
179. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
180. Low-molecular-weight heparin during instability in coronary artery disease
181. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
182. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network
183. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
184. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction
185. Interaction of ACE inhibitors and aspirin in patients with congestive heart failure
186. The basic pharmacology of ticlopidine and clopidogrel
187. Anriplatelet treatment with ticlopidine in unstable angina: A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group
188. Adverse haematological effects of ticlopidine. Prevention, recognition and management
189. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE)
190. Thrombotic thrombocytopenic purpura associated with clopidogrel
191. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
192. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes
193. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) Trial
194. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization
195. Low-molecular-weight heparins
196. Kinetics of the inhibition of thrombin by hirudin
197. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators
198. Hirulog in the treatment of unstable angina: Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
199. Clinical outcomes of bivalirudin for ischemic heart disease
200. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome
201. Anticoagulant treatment of unstable angina
202. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
203. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina
204. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina
205. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group)
206. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis
207. Reactivation of unstable angina after the discontinuation of heparin
208. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators
209. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
210. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I trial
211. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes
212. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
213. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: A randomized trial
214. A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-are coagulation monitoring in hospitalized patients with active thromboembolic disease: Antithrombotic Therapy Consortium Investigators
215. A new regimen for heparin use in acute coronary syndromes
216. Failure to achieve optimal anticoagulation with commonly used heparin regimens: A review of GUSTO IIb (abstr)
217. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
218. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. FRagmin In unstable Coronary artery disease study (FRIC)
219. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction FRAXIS: (FRAXiparine in Ischaemic Syndrome)
220. Platelet activation with unfractionated hepatin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
221. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
222. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]
223. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
224. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
225. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
226. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial
227. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study
228. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
229. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: Preliminary study
230. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study results
231. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis
232. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
233. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
234. Monitoring platelet GP IIb/IIIa [corrected] antagonist therapy
235. Platelet GPIIb-IIIa blockers
236. Potential non-glycoprotein IIb/IIIa effects of abciximab
237. 3 integrins
238. Clinical pharmacology of eptifibatide
239. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists
240. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383
241. Tirofiban
242. 3) inhibitors
243. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty The EPIC Investigation
244. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
245. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
246. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: Angiographic results from the PRISM-PLUS trial
247. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
248. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group
249. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using Integrilin therapy (PURSUIT) trial experience
250. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
251. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: Results of the Gruppo Italiano per lo Studio della ' Sopravvivenza nell'Infarto-1 study. The GISSI Investigators
252. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris
253. Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group
254. ACC/AHA guidelines for exercise testing: A report of the American College of Cardiology/American Heart Assodation Task Force on Practice Guidelines (Committee on Exercise Testing)
255. ACC/AHA guidelines for the clinical application of echocardiography: A report of the American College Of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography
256. Guidelines for the clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging). Developed in collaboration with the American Society of Nuclear Cardiology
257. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease
258. The predictive value of silent ischemia at an exercise test before discharge after an episode of unstable coronary artery disease. RISC Study Group
259. Treadmill exercise tests predischarge and six weeks post-myocardial infarction to detect abnormalities of known prognostic value
260. Exercise echocardiography is an accurate and cost-efficient technique for detection of coronary artery disease in women
261. Should the exercise test (ET) be performed at discharge or one month later after an episode of unstable angina or non-Q-wave myocardial infarction?
262. Analysis of death during the first twelve months among non-Q wave MI patients randomized to an 'invasive' vs. 'conservative' management strategy: Results from the VANQWISH trial
263. ACC/AHA guidelines for coronary angiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography)
264. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the Medicine versus Angiography in Thrombolytic Exclusion (MATE) trial
265. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators
266. RITA-2 Trial Participants. Coronary angioplasty versus medical therapy for angina: The second Randomised Intervention Treatment of Angina (RITA-2) trial
267. Risk stratification after myocardial infarction
268. Comparison of medical and surgical treatment for unstable angina pectoris: Results of a Veterans Administration Cooperative Study
269. The VA Cooperative Randomized Study of Surgery for Coronary Arterial Occlusive Disease, II: Subgroup with significant left main lesions
270. Abciximab provides cost efficient, safely expedited care for unstable angina
271. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris
272. ACC/AHA guidelines for percutaneous transluminal coronary angioplasty: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Percutaneous Transluminal Coronary Angioplasty)
273. ACC/AHA guidelines for coronary artery bypass graft surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Artery Bypass Graft Surgery)
274. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction
275. The Asymptomatic Cardiac Ischemia Pilot (ACIP) study: Design of a randomized clinical trial, baseline data and implications for a long-term outcome trial
276. Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study
277. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentte study
278. Outcome at one year after an invasive compared with a non-invasive strategy in unstable coronary artery disease: The FRISC II invasive randomized trial
279. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators
280. Long term outcome of patients with non-Q wave myocardial infarction with or without revascularization
281. An ischemia-guided strategy of cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes may be associated with improved outcomes
282. Factors associated with failure of medical therapy in patients with unstable angina and non-Q wave myocardial infarction: A TIMI IIIB database study
283. Angiographic morphology in unstable angina and its relation to transient myocardial ischemia and hospital outcome
284. Coronary angiographic findings after non-Q wave myocardial infarction: An analysis from the VANQWISH trial
285. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA trial)
286. Morbidity and use of medical resources in patients with chest pain and normal or near-normal coronary arteries
287. Psychosocial outcome and use of medical resources in patients with chest pain and normal or near-normal coronary arteries: A long-term follow-up study
288. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease
289. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty
290. Ten-year survival after coronary bypass surgery for unstable angina
291. Acute and late clinical outcome after rotational atherectomy for complex coronary disease
292. Myonecrosis after revascularization procedures
293. Abciximab decreases both the incidence arid magnitude of creatinine kinase elevation during rotational atherectomy
294. A pilot study of ReoPro with rotational atherectomy (RA) to reduce creatinine kinase (CK) elevation postprocedure
295. The transluminal extraction catheter device: Atherectomy and removal of an intracoronary thrombus
296. Extraction atherectomy during myocardial infarction in a patient with prior coronary artery bypass surgery
297. Results of percutaneous transluminal coronary angioplasty in unstable angina and non-Q-wave myocardial infarction: Observations from the TIMI IIIB trial
298. Coronary angioplasty in unstable angina: Contemporary experience
299. Immediate and follow-up results of the conservative coronary angioplasty strategy for unstable angina pectoris
300. Coronary angioplasty in unstable angina and stable angina: A comparison of success and complications
301. Usefulness of percutaneous transluminal coronary angioplasty for unstable angina pectoris after non-Q-wave acute myocardial infarction
302. Short-, medium-, and long-term follow-up after percutaneous transluminal coronary angioplasty for stable and unstable angina pectoris
303. Unstable angina: Report from a Canadian expert roundtable
304. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications
305. Comparison of results of intracoronary stenting in patients with unstable vs. stable angina
306. Results of coronary stenting for unstable versus stable angina pectoris
307. Intracoronary stenting and risk for major adverse cardiac events during the first month
308. Ticlopidine-aspirin as anti-thrombotic regimen for intracoronary stenting for unstable angina: Is there a need for further antiplatelet therapy?
309. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investlgators
310. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication
311. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
312. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis
313. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators
314. Improved cardiac outcomes in diabetic unstable angina/non-Q-wave myocardial infarction patients treated with tirofiban and heparin
315. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications
316. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II
317. Unstable angina pectoris
318. 10-Year results show duration of surgical advantage for patients with impaired ejection fraction
319. Medical compared with surgical management of unstable angina: 5-year mortality and morbidity in the Veterans Administration Study
320. Veterans Administration Cooperative Study for treatment of patients with unstable angina: Results in patients with abnormal left ventricular function
321. Coronary bypass surgery improves survival in high-risk unstable angina: Results of a Veterans Administration Cooperative study with an 8-year follow-up. Veterans Administration Unstable Angina Cooperative Study Group
322. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery
323. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: A multicenter randomized trial
324. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
325. Seven-Year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status
326. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation)
327. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease
328. Coronary revascularization in diabetic patients: A comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI)
329. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration
330. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina
331. Coronary Artery Surgery Study (CASS): A randomized trial of coronary artery bypass surgery. Survival data
332. Coronary angioplasty of the unstable angina related vessel in patients with multivessel disease
333. Comparison of effects of medical and surgical therapy on survival in severe angina pectoris and two-vessel coronary artery disease with and without left ventricular dysfunction: A Coronary Artery Surgery Study Registry Study
334. The physician's role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: Recommendations from the National Heart Attack Alert Program
335. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group
336. Risk stratification of patients with non-Q wave myocardial infarction: The critical role of ST segment depression. The Diltiazem Reinfarction Study Research Group
337. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators
338. Unstable angina: Good long-term outcome after a complicated early course
339. Depression and 18-month prognosis after myocardial infarction
340. A supportive-educative telephone program: Impact on knowledge and anxiety after coronary artery bypass graft surgery
341. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
342. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
343. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators
344. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators
345. When to start cholesterol-lowering therapy in patients with coronary heart disease
346. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (REduction of Cholesterol in Ischemia and Function of the Endothelium) trial
347. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction
348. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year
349. Standards of medical care for patients with diabetes mellitus (position statement)
350. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
351. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
352. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 3
353. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians
354. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia
355. Chest pain in women: Clinical, investigative, and prognostic features
356. Pathophysiological dilemma of syndrome X
357. Clinical manifestations of coronary artery disease: Chest pain in women
358. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry
359. Comparison of immediate and long-term outcome of coronary angioplasty performed for unstable angina and rest pain in men and women
360. Influence of gender on in-hospital clinical and angiographic outcomes and on one-year follow-up in the New Approaches to Coronary Intervention (NACI) registry
361. Comparison of the sensitivity and specificity of exercise electrocardiography in biased and unbiased populations of men and women
362. Comparison of exercise echocardiography with an exercise score to diagnose coronary artery disease in women
363. Logistic discriminant analysis improves diagnostic accuracy of exercise testing for coronary artery disease in women
364. Alternative diagnostic strategies for coronary artery disease in women: Demonstration of the usefulness and efficiency of probability analysis
365. Value of exercise treadmill testing in women
366. Dobutamine stress echocardiography in women with chest pain: Pilot phase data from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE)
367. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease
368. Sex differences in early and long-term results of coronary angioplasty in the NHLBI PTCA Registry
369. Results of percutaneous transluminal coronary angioplasty in women: 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry
370. The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty
371. Association of sex, physical size, and operative mortality after coronary artery bypass in the Coronary Artery Surgery Study (CASS)
372. Coronary artery surgery in women compared with men: Analyses of risks and long-term results
373. Gender differences for coronary angioplasty
374. Percutaneous transluminal coronary angioplasty in women compared with men
375. Similar results of percutaneous transluminal coronary angioplasty for women and men with postmyocardial infarction ischemia
376. Coronary heart disease: Therapeutic principles
377. Documentation of decline in morbidity in women undergoing coronary angioplasty(a report from the 1993-94 NHLBI Percutaneous Transluminal Coronary Angioplasty Registry). National Heart, Lung, and Blood Institute
378. Gender differences in mortality rates for coronary artery bypass surgery
379. Differences between men and women in hospital mortality associated with coronary artery bypass graft surgery. The Northern New England Cardiovascular Disease Study Group
380. Survival at 15 to 18 years after coronary bypass surgery for angina in women
381. Changing clinical characteristics of coronary surgery patients: Differences between men and women
382. Unstable coronary artery disease in post-menopausal women: Identifying patients with significant coronary artery disease by basic clinical parameters and exercise test. IRIS Study Group
383. Better outcome for women compared with men undergoing coronary revascularization: A report from the Bypass Angioplasty Revascularization Investigation (BARI)
384. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: The Bypass Angioplasty Revascularization Investigation (BARI)
385. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study
386. Recombinant hirudin for unstable angina pectoris: A multicenter, randomized angiographic trial
387. Coronary angioplasty in diabetic patients: The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry
388. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty
389. Prognostic significance of a predischarge exercise test in risk stratification after unstable angina pectoris
390. One-year prognosis in patients hospitalized with a history of unstable angina pectoris
391. Outcome of unstable angina in patients with diabetes mellitus
392. Grupo de Estudio del Trifusal en la Angina Inestable
393. Unstable angina: Special considerations in the post-bypass patient
394. Silent myocardial ischemia: Role of subclinical neuropathy in patients with and without diabetes
395. Exertional myocardial ischemia in diabetes: A quantitative analysis of anginal perceptual threshold and the influence of autonomic function
396. Abnormal cardiac function in diabetic patients with autonomic neuropathy in the absence of ischemic heart disease
397. Unstable angina: A comparison of angioscopic findings between diabetic and nondiaberic patients
398. Coronary bypass surgery: Is the operation different today?
399. Eight year mortality in the Emory Angioplasty vs Surgery Trial (EAST)
400. Importance of considering atherosclerosis progression When choosing a coronary revascularization strategy: The diabetes-percutaneous transluminal coronary angioplasty dilemma
401. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty
402. Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). CAVEAT-I Investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial
403. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial. EPILOG Investigators
404. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
405. Preoperative and operative predictive variables of late clinical events following saphenous vein coronary artery bypass graft surgery
406. Previous coronary artery bypass grafting as an adverse prognostic factor in unstable angina pectoris
407. Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation
408. Atherosclerosis in aortocoronary bypass grafts: Morphologic study and risk factor analysis 6 to 12 years after surgery
409. Morphologic observations after percutaneous transluminal balloon angioplasty of early and late aortocoronary saphenous vein bypass grafts
410. Ruptured atheromatous plaques in saphenous vein coronary artery bypass grafts: A mechanism of acute, thrombotic, late graft occlusion
411. Progression of native coronary artery disease at 10 years: Insights from a randomized study of medical versus surgical therapy for angina
412. Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery
413. Previously undiagnosed variant angina as a cause of chest pain after coronary artery bypass surgery
414. Sudden occlusion of a saphenous vein bypass graft relieved by direct injection of nitroglycerin
415. The influence of residual disease after coronary bypass on the 5-year survival rate of 1274 men with coronary artery disease
416. Morphologic comparison of atherosclerotic lesions in native coronary arteries and saphenous vein graphs with intracoronary angioscopy in patients with unstable angina
417. Thallium-201 myocardial imaging before and after coronary revascularization: Assessment of regional myocardial blood flow and graft patency
418. Thailium-201 myocardial perfusion scintigrams in the evaluation of aorto-coronary saphenous bypass surgery
419. Prevention of distal embolization during saphenous vein graft lesion angioplasty: Experience with a new temporary occlusion and aspiration system
420. Comparison of outcome of patients with unstable angina and non-Q-wave acute myocardial infarction with and without prior coronary artery bypass grafting (Thrombolysis in Myocardial Ischemia III Registry)
421. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators
422. The effect of coronary reoperation on the survival of patients with stenoses in saphenous vein bypass grafts to coronary arteries
423. Vein graft disease: The clinical impact of stenoses in saphenous vein bypass grafts to coronary arteries
424. The aging heart: Structure, function, and disease
425. Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study
426. Geriatric cardiology: When exercise stress testing is justified
427. Comparative effects of aging and coronary heart disease on submaximal and maximal exercise
428. Principles and practice of pharmacotherapy
429. Management of drug therapy in the elderly
430. Changing outcome of angioplasty in the elderly
431. Comparison of six-month outcome of coronary artery stenting in patients <65, 65-75, and >75 years of age
432. Changes in mortality after myocardial revascularization in the elderly: The national Medicare experience
433. Coronary angioplasty versus bypass surgery in patients >70 years old matched for ventricular function
434. Angioplasty versus coronary artery bypass in octogenarians
435. Results of direct percutaneous transluminal coronary angioplasty in octogenarians
436. Predicting early and intermediate-term outcome of coronary angioplasty in the elderly
437. Coronary angioplasty for elderly patients with 'high risk' unstable angina: Short-term outcomes and long-term survival
438. Percutaneous transluminal coronary angioplasty in patients aged > or = 90 years
439. Fifteen-year trends in risk severity and operative mortality in elderly patients undergoing coronary artery bypass graft surgery
440. Cardiac surgery m the octogenarian: Perioperative outcome and clinical follow-up
441. Survival analysis of octogenarian patients with coronary artery disease managed by elective coronary artery bypass surgery versus conventional medical treatment
442. Performance stares and outcome after coronary artery bypass grafting in persons aged 80 to 93 years
443. Cardiac complications of cocaine abuse
444. Cardiovascular complications of cocaine
445. The effects of acute and chronic cocaine use on the heart
446. Cocaine-induced myocardial ischemia and infarction: Pathophysiology, recognition, and management
447. Cocaine-induced myocardial ischemia
448. Clinical toxicology of cocaine
449. Effect of cocaine on coronary artery dimensions in atherosclerotic coronary artery disease: Enhanced vasoconstriction at sites of significant stenoses
450. Cocaine-induced coronary-artery vasoconstriction
451. Recurrent myocardial infarction associated with cocaine abuse in a young man with normal coronary arteries: Evidence for coronary artery spasm culminating in thrombosis
452. Cocaine and cardiovascular function in dogs: Effects on heart and peripheral circulation
453. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin
454. Cocaine and vasospasm
455. Myocardial ischemia during cocaine withdrawal Ann Intern Med
456. Cocaine-induced small vessel spasm in isolated rat hearts
457. Platelet responsiveness and biosynthesis of thromboxane and prostacyclin in response to in vitro cocaine treatment
458. Cocaine and cardiovascular diseases
459. Simultaneous acute thrombosis of two major coronary arteries following intravenous cocaine use
460. Prospective multicenter evaluation og cocaine-associated chest pain. Cocaine Associated Chest Pain (COCHPA) Study Group
461. Cocaine and chest pain: Clinical features and outcome of patients hospitalized to rule out myocardial infarction
462. Quantitative analysis of amounts of coronary arterial narrowing in cocaine addicts
463. Cardiovascular effects of cocaine: An autopsy study of 40 patients
464. Cocaine-induced aortic dissection
465. Cardiovascular manifestations of cocaine abuse: A case of recurrent dilated cardiomyopathy
466. Reversible cardio-myopathy associated with cocaine intoxication
467. Successful intracoronary thrombolysis in cocaine-associated acute myocardial infarction
468. The management of cocaine-associated myocardial ischemia
469. An evaluation of cocaine-induced chest pain
470. Cocaine-associated myocardial infarction. Mortality and complications. Cocaine-Associated Myocardial Infarction Study Group
471. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade
472. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans
473. Angina pectoris II
474. Electrocardiographic changes during brief angina pectoris
475. Coronary vasospasm in angina pectoris
476. Fluctuation of spastic location in patients with vasospastic angina: A quantitative angiographic study
477. Intravascular ultrasound detection of atherosclerosis at the site of focal vasospasm in angiographically normal or minimally narrowed coronary segments
478. 'Variant' angina: One aspect of a continuous spectrum of vasospastic myocardial ischemia. Pathogenetic mechanisms, estimated incidence and clinical and coronary arterio-graphic findings in 138 patients
479. Long-term prognosis of patients with variant angina
480. Organic coronary stenosis in Prinzmetal's variant angina
481. Hyperventilation and ergonovine tests in Prinzmetal's variant angina pectoris in men
482. Coronary arteriography and left ventriculography during spontaneous and exercise-induced ST segment elevation in patients with variant angina
483. Provocation of coronary artery spasm by the cold pressor test: Hemodynamic, atteriographic and quantitative anglographic observations
484. Circadian variation of plasma fibrinopeptide A level in patients with variant angina
485. Statistical analysis of clinical risk factors for coronary artery spasm: Identification of the most important determinant
486. Cigarette smoking is a major risk factor for coronary spasm
487. Clinical characteristics associated with sudden death in patients with variant angina
488. Role of coronary vasospasm in the pathogenesis of myocardial infarction: Study in patients with no significant coronary stenosis
489. Cardiac arrest and sudden unexpected death in variant angina: Complications of coronary spasm that can occur in the absence of Severe organic coronary stenosis
490. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes
491. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina
492. Prinzmetal's variant form of angina as a manifestation of alpha-adrenergic receptor-mediated coronary artery spasm: Documentation by coronary arteriography
493. Endothelium derived vasoactive factors, I: Endothelium-dependent relaxation
494. Induction of coronary artery spasm by acetylcholine in patients with variant angina: Possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm
495. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1β
496. Prinzmetal's variant angina
497. Hyperventilation as a specific test for diagnosis of coronary artery spasm
498. Ergonovine echocardiography for coronary spasm: Facts and wishful thinking
499. Calcium channel antagonists in the management of anginal syndromes: Changing concepts in relation to the role of coronary vasospasm Prog Cardiovasc Dis
500. Randomized placebo-controlled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group
501. Efficacy of isosorbide-5-mononitrate versus nifedipine in preventing spontaneous and ergonovine-induced myocardial ischaemia: A double-blind, placebo-controlled study
502. Long-term prognosis for patients with variant angina and influential factors
503. Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X
504. Cardiac syndrome X: Clinical characteristics and left ventricular function: Long-term follow-up study
505. Angina pectoris caused by coronary microvascular spasm
506. Coronary hemodynamics and myocardial metabolism in patients with syndrome X: Response to pacing stress
507. Comparison of left ventricular function and volumes during transesophageal atrial pacing combined with two-dimensional echocardiography in patients with syndrome X, atherosclerotic coronary artery disease, and normal subjects
508. Seven year survival of patients with normal or near normal coronary arteriograms: A CASS registry study
509. Four-year follow-up study in patients with angina pectoris and normal coronary arteriograms ('syndrome X')
510. Efficacy of calcium channel blocker therapy for angina pectoris resulting from small-vessel coronary artery disease and abnormal vasodilator reserve
511. Comparison of verapamil versus propranolol therapy in syndrome X
512. Lack of evidence for alpha-adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X
513. Imipramine in patients with chest pain despite normal coronary angiograms
514. Short, term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms
515. 17-Beta-Estradiol therapy lessens angina in postmenopausal women with syndrome X